Hayder Saeed1, Reema Patel2, Jigisha Thakkar3, Lames Hamoodi4, Li Chen5, John L Villano2. 1. Department of Internal Medicine, Division of Hematology/BMT, Lexington, KY 40536, USA. Electronic address: hsa222@uky.edu. 2. Department of Internal Medicine, Division of Medical Oncology, Lexington, KY 40536, USA. 3. Department of Neurology, University of Kentucky, Lexington, KY 40536, USA. 4. Department of Pathology, University of Kentucky, Lexington, KY 40536, USA. 5. Biostatistics and Bioinformatics Shared Resources, Markey Cancer Center, University of Kentucky, Lexington, KY 40536, USA.
Abstract
BACKGROUND: Most metastatic spinal cord lesions are located either in the intradural, extramedullary, or in the epidural compartments. Intramedullary spinal cord metastasis (ISCM) is a rare central nervous system spread of cancer. The aim of this report was to evaluate ISCM in the published literature. METHODS: A literature review of PubMed from 1960 to 2016 was undertaken for the publications having demographic, clinical, histological, and outcome data. RESULTS: A total of 59 relevant papers were identified, showing 128 cases of intramedullary metastasis from lung cancer. The incidence of lung cancer as the primary malignancy with intramedullary metastasis was 56%. The median time from diagnosis of primary to intramedullary metastasis was 6months. Survival improved with multimodality therapy compared to monotherapy (4monthsvs. 6.3months) (hazard ratio=0.501; 95% confidence interval, 0.293-0.857). CONCLUSION: Lung cancer is the predominant cause of intramedullary involvement of the spinal cord. Overall prognosis is poor, although a multimodality approach was associated with improved survival.
BACKGROUND: Most metastatic spinal cord lesions are located either in the intradural, extramedullary, or in the epidural compartments. Intramedullary spinal cord metastasis (ISCM) is a rare central nervous system spread of cancer. The aim of this report was to evaluate ISCM in the published literature. METHODS: A literature review of PubMed from 1960 to 2016 was undertaken for the publications having demographic, clinical, histological, and outcome data. RESULTS: A total of 59 relevant papers were identified, showing 128 cases of intramedullary metastasis from lung cancer. The incidence of lung cancer as the primary malignancy with intramedullary metastasis was 56%. The median time from diagnosis of primary to intramedullary metastasis was 6months. Survival improved with multimodality therapy compared to monotherapy (4monthsvs. 6.3months) (hazard ratio=0.501; 95% confidence interval, 0.293-0.857). CONCLUSION:Lung cancer is the predominant cause of intramedullary involvement of the spinal cord. Overall prognosis is poor, although a multimodality approach was associated with improved survival.
Authors: Felix Ehret; Carolin Senger; Markus Kufeld; Christoph Fürweger; Melina Kord; Alfred Haidenberger; Paul Windisch; Daniel Rueß; David Kaul; Maximilian Ruge; Christian Schichor; Jörg-Christian Tonn; Alexander Muacevic Journal: Cancers (Basel) Date: 2021-01-15 Impact factor: 6.639
Authors: Marion Tonneau; Raphaëlle Mouttet-Audouard; Florence Le Tinier; Xavier Mirabel; David Pasquier Journal: BMC Cancer Date: 2021-10-30 Impact factor: 4.430